[1] Wang Yajun, Lv Yonghui,.Clinical Effect of Xieli Decoction in Treating Active Ulcerative Colitis and Its Effect on NF － α、CＲP [J]. Journal of Shaanxi University of Traditional Chinese Medicine, 2017, (05): 65-68. [doi: 10.13424/j.cnki.jsctcm.2017.05.022]
Clinical Effect of Xieli Decoction in Treating Active Ulcerative Colitis and Its Effect on NF － α、CＲP
- Article number:
- 2096－1340(2017)03－0065－04
- Keywords:
- Xieli decoction; ulcerative colitis; active; TNF － α; CＲP
- ZTFLH:
- Ｒ574.62
- Code:
- A
- Abstract:
- Objective: To investigate clinical effect of Xieli decoction in treating active ulcerative colitis ( UC) and its effect on NF － α、CＲP concentration in patients’serum． Methods: By random number table，60 cases of mild － to－ moderate active UC patients meeting the diagnostic standard were randomly divided into treatment group and control group with 30 cases in each． The cases of treatment group were given modified Xieli decoction and the cases of control group were orally given Mesalazin enteric － coated tablets． The course for each group was 4 weeks． Finally，the clinical effect，TCM symptom scores and NF － α、CＲP concentration changes in patients’serum of the two groups before and after treatment were compared，and the adverse reaction of the cases during the treatment were recorded． Ｒesults: Clinical effect of the treatment group was superior to that of the control group，the difference was statistically significant( P ＜ 0． 05) ． The comparison of TCM symptom scores between the two groups before and after treatment had statistical significance( P ＜ 0． 05) ， the treatment group was superior to that of the control group． After the treatment，NF － α、CＲP concentrations in patients’serum were lower than those of the control group， the difference was statistically significant( P ＜0． 05) ． The differences of colonoscopic mucosal integral between the two groups before and after the treatment had no statistical significance( P ＞ 0． 05) ． Conclusion: Xieli decoction is effective in treating active UC，it is safe and worthy of clinical application．
References:
[1]中华医学会消化病学分会炎症性肠病学组． 炎症性肠病诊断与治疗的共识意见［J]． 中华内科杂志，2012，51( 10) : 818 － 831．
[2]中华中医药学会脾胃病分会． 溃疡性结肠炎中医诊疗共识( 2009) ［J]． 中国中西医结合杂志，2010，30 ( 5) :527 － 532．
[3]中华医学会消化病学分会炎症性肠病协作组． 对我国炎症性肠病诊断治疗规范的共识意见( 2007 年，济南)［J]． 中华消化杂志，2007，27( 8) : 545 － 550．
[4]郑莜萸． 中药新药临床研究指导原则( 试行) ［M]． 北京: 中国医药科技出版社，2002: 129 － 134．
[5]Baron JH，Connell AM，Lennard － Jones JE． Variation between observers in describing mucosal appearances in proctocolitis［J]． Br Med J，1964，1( 5375) : 89 － 92．
[6]王亚军，吕永慧，董晶，等． 溃疡性结肠炎中医辨证分型与TNF － α 的相关性研究［J]． 中国中西医结合消化杂志，2014，22( 9) : 525 － 528．
[7]王万卷，陈丽，王晓鹏，等． 寻常型银屑病皮损中肿瘤坏死因子－ α、基质金属蛋白酶－ 9 及其抑制剂－ 1 的表达［J]． 西安交通大学学报( 医学版) ，2007，28( 3) : 322－ 324．
[8]SZLOSAＲEK PW，BALKWILL FＲ． Tumor necrosis factor a1pha: a potential target for the therapy of solid tumors［J]． Lancet Oncol，2003，4( 9) : 565 － 573．
[9]冯百岁，刘占举，牛正先． 美沙拉秦治疗溃疡性结肠炎的临床疗效及对血清TNF － α 和IL － 8 的影响［J]． 郑州大学学报( 医学版) ，2006，41( 5) : 830 － 833．
[10]罗立成． C 反应蛋白在溃疡性结肠炎中的临床价值［J]． 临床合理用药杂志，2012，5( 11) : 108 － 109．
Memo
收稿日期:2017－04－06编辑:方亚利
＊＊＊
基金项目:广东省阳江市卫计局科研立项项目(阳卫计2015023)
通讯作者:吕永慧(1957－)，女，主任中医师，教授，博士研究生导师，主要研究方向:炎症性肠病的临床研究。E－mail:zdjlyh@126．com